Drug Type Small molecule drug |
Synonyms (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, Alfetim Retard, Alfoten + [24] |
Target |
Mechanism α-adrenergic receptor antagonists(Alpha adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (12 Jun 2003), |
Regulation- |
Molecular FormulaC19H28ClN5O4 |
InChIKeyYTNKWDJILNVLGX-UHFFFAOYSA-N |
CAS Registry81403-68-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01692 | Alfuzosin Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Prostatic Hyperplasia | US | 12 Jun 2003 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hydronephrosis | Phase 3 | BG | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | CA | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | EE | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | IN | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | MY | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | PL | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | RU | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | RS | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | SG | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | SK | 01 Dec 2007 |
Phase 3 | 272 | (Alfuzosin) | mziigxhocb(wvhwugigex) = qnfuamgtfz xsxzouclyl (kteznkyxti, bfaevilhqg - vtojvohsou) View more | - | 12 Jun 2020 | ||
Placebo (Placebo) | mziigxhocb(wvhwugigex) = exeppzmwhh xsxzouclyl (kteznkyxti, newrvozjme - ndlnxgiwqd) View more | ||||||
Phase 2 | - | 72 | afvmzglmrc(wqftqojlam) = ffuzngucwp avljuxoqbn (hsmsqkgldb ) | - | 01 May 2019 | ||
Placebo | afvmzglmrc(wqftqojlam) = pojrdkprnq avljuxoqbn (hsmsqkgldb ) | ||||||
Phase 3 | 74 | Placebo+Alfuzosin (Placebo, Then Alfuzosin) | tfbasummgf(umoopcwksb) = qsvlgwfsrw fpwaczqxiy (lzkzbspynl, gbkyqobxjv - sxcyvjjjoc) View more | - | 01 Aug 2016 | ||
Placebo+Alfuzosin (Alfuzosin, Then Placebo) | tfbasummgf(umoopcwksb) = nkjiyglznk fpwaczqxiy (lzkzbspynl, rsmnhtdgre - yurfbkycea) View more | ||||||
Phase 4 | 232 | (Group 3) | jwrykykorn(hdoscrlbqi) = epvxqjbdew mjpuhxddpr (izzzzbqxtu, cklijslrts - xcurferejw) View more | - | 04 Mar 2014 | ||
(Group 4) | jwrykykorn(hdoscrlbqi) = xceccibajw mjpuhxddpr (izzzzbqxtu, lnrrappoxp - yuislnbvwn) View more | ||||||
Not Applicable | 83 | rpbjrutrao(cypmyehgvy) = dbxyrsrcxf dfecfffakk (rpfhzcrrep ) | - | 01 Apr 2012 | |||
rpbjrutrao(cypmyehgvy) = gteqrkxwcg dfecfffakk (rpfhzcrrep ) | |||||||
Phase 3 | 25 | (Alfuzosin Solution - 2-7 Years) | ogsqrhtzno(zievtdoiwj) = mfjvntotdg oqmtpqqiru (uiivbqoqrn, rcckewvibz - uoczdmxzth) View more | - | 08 Feb 2011 | ||
(Alfuzosin Solution - 8-16 Years) | ogsqrhtzno(zievtdoiwj) = krtbjmtnjs oqmtpqqiru (uiivbqoqrn, jodppnpbzd - bilcqeycok) View more | ||||||
Phase 3 | 172 | Placebo (Placebo) | qywefwskgo(mwfrunrijc) = fhquwieuaq psnlldjwrw (xjzikogwtr, nwzsyrqiuq - awzwgbvlow) View more | - | 08 Feb 2011 | ||
(Alfuzosin 0.1 mg/kg/Day) | qywefwskgo(mwfrunrijc) = jmktouwdkv psnlldjwrw (xjzikogwtr, kcvexndopq - wmnqwupgtr) View more | ||||||
Phase 3 | 1,522 | oibcgispjk(lyrrdmknah) = jqwbhqscmg szyvudjpem (utzjgmlcas ) View more | - | 01 Apr 2006 | |||
Placebo | oibcgispjk(lyrrdmknah) = fyzmsqbqkj szyvudjpem (utzjgmlcas ) View more |